scholarly journals The impact of laboratory characteristics on molecular detection of respiratory syncytial virus in a European multicentre quality control study

2008 ◽  
Vol 14 (12) ◽  
pp. 1173-1176 ◽  
Author(s):  
T.J. Meerhoff ◽  
W.G. MacKay ◽  
A. Meijer ◽  
W.J. Paget ◽  
H.G.M. Niesters ◽  
...  
Keyword(s):  
Quality Control ◽  
Respiratory Syncytial Virus ◽  
Molecular Detection ◽  
Quality Control Study ◽  
Syncytial Virus ◽  
The Impact ◽  
Control Study

scholarly journals 1719. Respiratory Syncytial Virus-Associated Hospitalization Rates among US Infants: A Systematic Review and Meta-Analysis

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S843-S843
Author(s):  
John M McLaughlin ◽  
Farid L Khan ◽  
Heinz-Josef Schmitt ◽  
Yasmeen Agosti ◽  
Luis Jodar ◽  
...  
Keyword(s):  
Public Health ◽  
Respiratory Syncytial Virus ◽  
Active Surveillance ◽  
Meta Analysis ◽  
The United States ◽  
Administrative Claims ◽  
Prevention Strategies ◽  
Hospitalization Rates ◽  
Syncytial Virus ◽  
The Impact

Abstract Background Understanding the true magnitude of infant respiratory syncytial virus (RSV) burden is critical for determining the potential public-health benefit of RSV prevention strategies. Although global reviews of infant RSV burden exist, none have summarized data from the United States or evaluated how RSV burden estimates are influenced by variations in study design. Methods We performed a systematic literature review and meta-analysis of studies describing RSV-associated hospitalization rates among US infants. We also examined the impact of key study characteristics on these estimates. Results After review of 3058 articles through January 2020, we identified 25 studies with 31 unique estimates of RSV-associated hospitalization rates. Among US infants < 1 year of age, annual rates ranged from 8.4 to 40.8 per 1000 with a pooled rate= 19.4 (95%CI= 17.9–20.9). Study type was associated with RSV hospitalization rates (P =.003), with active surveillance studies having pooled rates per 1000 (11.1; 95%CI: 9.8–12.3) that were half that of studies based on administrative claims (21.4; 95%CI: 19.5–23.3) or modeling approaches (23.2; 95%CI: 20.2–26.2). Conclusion Applying the pooled rates identified in our review to the 2020 US birth cohort suggests that 73,680 to 86,020 RSV-associated infant hospitalizations occur each year. To date, public-health officials have used conservative estimates from active surveillance as the basis for defining US infant RSV burden. The full range of RSV-associated hospitalization rates identified in our review better characterizes the true RSV burden in infants and can better inform future evaluations of RSV prevention strategies. Disclosures John M. McLaughlin, PhD, Pfizer (Employee, Shareholder) Farid L. Khan, MPH, Pfizer (Employee, Shareholder) Heinz-Josef Schmitt, MD, Pfizer (Employee, Shareholder) Yasmeen Agosti, MD, Pfizer (Employee, Shareholder) Luis Jodar, PhD, Pfizer (Employee, Shareholder) Eric Simões, MD, Pfizer (Consultant, Research Grant or Support) David L. Swerdlow, MD, Pfizer (Employee, Shareholder)

Comparison of prostate cancer treatment in two institutions: a quality control study

1999 ◽  
Vol 45 (4) ◽  
pp. 1055-1062 ◽  
Author(s):  
Coen Rasch ◽  
Peter Remeijer ◽  
Peter C.M Koper ◽  
Gert J Meijer ◽  
Joep C Stroom ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Quality Control ◽  
Cancer Treatment ◽  
Prostate Cancer Treatment ◽  
Quality Control Study ◽  
Control Study

scholarly journals Determining the Seasonality of Respiratory Syncytial Virus in the United States: The Impact of Increased Molecular Testing

2017 ◽  
Vol 216 (3) ◽  
pp. 345-355 ◽  
Author(s):  
Claire M Midgley ◽  
Amber K Haynes ◽  
Jason L Baumgardner ◽  
Christina Chommanard ◽  
Sara W Demas ◽  
...  
Keyword(s):  
United States ◽  
Respiratory Syncytial Virus ◽  
The United States ◽  
Molecular Testing ◽  
Syncytial Virus ◽  
The Impact

Measurement of histamine: A quality control study

1980 ◽  
Vol 66 (4) ◽  
pp. 295-298 ◽  
Author(s):  
Gerald J. Gleich ◽  
William M. Hull
Keyword(s):  
Quality Control ◽  
Quality Control Study ◽  
Control Study

scholarly journals Construction and characterization of recombinant vaccinia viruses co-expressing a respiratory syncytial virus protein and a cytokine

2001 ◽  
Vol 82 (9) ◽  
pp. 2107-2116 ◽  
Author(s):  
Teresa R. Johnson ◽  
Julie E. Fischer ◽  
Barney S. Graham
Keyword(s):  
Respiratory Syncytial Virus ◽  
Immune Responses ◽  
Vaccinia Virus ◽  
Antigen Expression ◽  
Virus Protein ◽  
Recombinant Vaccinia ◽  
Vaccinia Viruses ◽  
Ifn Γ ◽  
Syncytial Virus ◽  
The Impact

Recombinant vaccinia viruses are well-characterized tools that can be used to define novel approaches to vaccine formulation and delivery. While vector co-expression of immune mediators has enormous potential for optimizing the composition of vaccine-induced immune responses, the impact on antigen expression and vector antigenicity must also be considered. Co-expression of IL-4 increased vaccinia virus vector titres, while IFN-γ co-expression reduced vaccinia virus replication in BALB/c mice and in C57BL/6 mice infected with some recombinant viruses. Protection against respiratory syncytial virus (RSV) challenge was similar in mice immunized with vaccinia virus expressing RSV G glycoprotein and IFN-γ, even though the replication efficiency of the vector was diminished. These data demonstrate the ability of vector-expressed cytokine to influence the virulence of the vector and to direct the development of selected immune responses. This suggests that the co-expression of cytokines and other immunomodulators has the potential to improve the safety of vaccine vectors while improving the immunogenicity of vaccine antigens.

scholarly journals Disability-adjusted Life Years for respiratory syncytial virus in children under 2 years

2020 ◽  
Author(s):  
jefferson buendia ◽  
Fernando Polack ◽  
Juana Patricia Sanchez Villamil
Keyword(s):  
Respiratory Syncytial Virus ◽  
Statistical Parameter ◽  
Epidemiological Surveillance ◽  
Years Of Life Lost ◽  
Disability Adjusted Life Years ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Rsv Infection ◽  
Syncytial Virus ◽  
The Impact

Abstract BACKGROUND: Respiratory syncytial virus infection is the leading cause of bronchiolitis in Colombia. There is growing evidence about the impact of Respiratory syncytial virus on society in terms of years of life lost due to this condition. The objective of the present study is to determine the Disability-Adjusted Life Years for respiratory syncytial virus in children under 2 years in ColombiaMETHODS: Data from the national epidemiological surveillance system were used to estimate DALYs, calculated from the sum of years of life lost and years lived with disability due to RSV infection in Colombia. A bootstrapped method with 10000 iterations was used to estimate each statistical parameter using the package DALY calculator in R. RESULTS: In 2019, 260 873 years of life (CI95% 208 180- 347 023) were lost due to RSV bronchiolitis in Colombian children under 2 years. The estimated rate was 20 DALYs / 1000 person-year (95% CI 16 – 27).CONCLUSION: This is the first report estimating the impact of RSV bronchiolitis morbidity and mortality in Colombia. The findings of the present study suggest that the actual burden and cost of bronchiolitis due to RSV is high. Prevention strategies, such as RSV vaccination, to reduce morbidity associated with RSV infection should be encouraged in our country.

Sign in / Sign up

Export Citation Format

Share Document